Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 6/20 | 0.39 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | TK1 | P04183 | 3/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219675 | 0.82 | TDP1 (0.36) | TK2 | |
| SCHEMBL1322836 | 0.82 | RNASE1 (0.48) | TK1RNASE1 | |
| SCHEMBL2112758 | 0.79 | TYMP (0.40) | TK1TYMP | |
| SCHEMBL5220787 | 0.79 | TERT (0.32) | TK2TERT | |
| SCHEMBL8592454 | 0.79 | RNASE1 (0.44) | TK2TERTTK1RNASE1TYMP | |
| SCHEMBL5134596 | 0.78 | TK1 (0.40) | TK2TK1TYMP | |
| SCHEMBL9294173 | 0.76 | TYMP (0.37) | TK2TK1TYMP | |
| SCHEMBL7070203 | 0.76 | RNASE1 (0.47) | TERTTK1RNASE1 | |
| SCHEMBL7267312 | 0.75 | TK2 (0.42) | TK2TK1TYMP | |
| SCHEMBL6536270 | 0.74 | TK1 (0.39) | TK2TK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | MANOHARAN MUTHIAH | 2007-05-31 | — | — | US | disclosed |
| US-7119184-B2 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1222309-B1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1100809-B1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6617442-B1 | Divided into two portions, one of which supports cleavage of target RNA; use in enhancing antisense therapies | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TK2 1005/4885TERT 3287/4885TK1 661/4885 |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | TK2 272/4885TERT 1557/4885TK1 407/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TK2 1005/4885TERT 3287/4885TK1 661/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | TK2 260/4885TERT 1672/4885TK1 433/4885 |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | RNASEH1, RNGTT, ADAR | TK2 853/4885TERT 3138/4885TK1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.